Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma in the era of targeted therapy: a bibliographic review

Faba, Oscar; Brookman-May, Sabine; Linares, Estefania; Breda, Alberto; Pisano, Francesca; Subiela, José; Sanguedolce, Francesco; Brausi, Maurizio; Palou, Joan
December 2017
World Journal of Urology;Dec2017, Vol. 35 Issue 12, p1807
Academic Journal
Purpose: To evaluate the role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC), against a background of lack of evidence following the introduction of targeted therapy. Methods: A literature review was performed in January 2017 using the MEDLINE/PubMed and EMBASE databases. The PRISMA guidelines were followed for conduct of the study. Two authors independently screened the 270 papers retrieved from the search, and the finally selected publications were identified by consensus between the two reviewers. A total of 55 studies were included in the present review. Results: Globally, the indications for CN have decreased over recent years. Although current guidelines consider CN an adequate option in selected patients based on prospective studies in the cytokine era, evidence for CN in the era of targeted therapy is based on retrospective studies only. Conclusions: The results of ongoing prospective studies are still awaited. Retrospective data suggest that young male patients with oligometastatic disease and a good performance status can be considered suitable surgical candidates who may benefit from CN.


Related Articles

  • Surgical management of metastatic renal cell carcinoma in the era of targeted therapies. Krabbe, Laura-Maria; Haddad, Ahmed; Westerman, Mary; Margulis, Vitaly // World Journal of Urology;Jun2014, Vol. 32 Issue 3, p615 

    Background: Cytoreductive nephrectomy (CN) has been considered standard management for patients with metastatic renal cell carcinoma (mRCC) for over a decade. This practice, based on evidence from the immunotherapy era, has now come into question with the dramatic shift in management of mRCC...

  • Hematuria following kidney tumorectomy: can it hide an arteriovenous fistula? Pavan, Nicola; Liguori, Giovanni; Vedovo, Francesca; Bucci, Stefano; Bertolotto, Michele; Trombetta, Carlo // Urologia;Jul-Sep2015, Vol. 82 Issue 3, p191 

    We present the case and radiologic images of a 64-year-old man who presented with gross hematuria and fever 2 months after undergoing retroperitoneal partial nephrectomy for a 4.7 × 4.6 cm papillary renal cell carcinoma. Angio- TC demonstrated an aneurysmatic dilatation of the anterior...

  • Chest X-ray in the follow-up of renal cell carcinoma. Doornweerd, B.; Jong, I.; Bergman, L.; Ananias, H. // World Journal of Urology;Aug2014, Vol. 32 Issue 4, p1015 

    Purpose: To evaluate the value of chest X-ray in the follow-up of surgically treated T1-3N0M0 renal cell carcinoma. Methods: We performed retrospective analysis of patients that underwent surgical treatment of a localized renal cell carcinoma (T1-3N0M0) between January 1993 and July 2010. Data...

  • Renal tumor size is an independent prognostic factor for overall survival in von Hippel-Lindau disease. Kwon, Taekmin; Jeong, In; Pak, Sahyun; You, Dalsan; Song, Cheryn; Hong, Jun; Ahn, Hanjong; Kim, Choung-Soo // Journal of Cancer Research & Clinical Oncology;Jul2014, Vol. 140 Issue 7, p1171 

    Objectives: To evaluate the effect of renal cell carcinoma (RCC) on survival in von Hippel-Lindau (VHL) disease and to assess the relationship between tumor size and survival. Materials and methods: In this retrospective cohort study, the medical records of 72 patients who presented with VHL...

  • Efficacy and safety of temsirolimus in Japanese patients with metastatic renal cell carcinoma on hemodialysis. Miyake, Hideaki; Harada, Ken-ichi; Kusuda, Yuji; Fujisawa, Masato // International Journal of Clinical Oncology;Dec2013, Vol. 18 Issue 6, p1054 

    Background: We retrospectively investigated the efficacy and safety of temsirolimus, an inhibitor of the mammalian target of rapamycin, in patients with metastatic renal cell carcinoma (mRCC) on hemodialysis (HD). Methods: This study included ten HD patients who were diagnosed with mRCC...

  • Improved survival in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy in the era of targeted therapy. Sakai, Iori; Miyake, Hideaki; Hinata, Nobuyuki; Fujisawa, Masato // International Journal of Clinical Oncology;Aug2014, Vol. 19 Issue 4, p674 

    Background: We aimed to review our clinical experience of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma (mRCC) and to identify factors associated with postoperative prognosis in these patients. Methods: This study included a total of 164 Japanese patients with mRCC...

  • Risk of End-Stage Renal Disease after Cancer Nephrectomy in Taiwan: A Nationwide Population-Based Study. Lin, Wei-Yu; Liang, Fu-Wen; Lu, Tsung-Hsueh // PLoS ONE;May2015, Vol. 10 Issue 5, p1 

    Background: The conclusions of population-based studies examining the risk of developing end-stage renal disease (ESRD) after nephrectomy among patients with renal cell carcinoma (RCC) remain inconclusive. In this study, we sought to examine whether patients with RCC undergoing radical...

  • Trends in the Use of Nephron-Sparing Surgery over 7 Years: An Analysis Using the R.E.N.A.L. Nephrometry Scoring System. Shin, Seung Jea; Ko, Kwang Jin; Kim, Tae Sun; Ryoo, Hyun Soo; Sung, Hyun Hwan; Jeon, Hwang Gyun; Jeong, Byong Chang; Seo, Seong Il; Lee, Hyun Moo; Choi, Han Yong; Jeon, Seong Soo // PLoS ONE;11/24/2015, Vol. 10 Issue 11, p1 

    Objective: To analyze trends in the use of partial nephrectomy, we evaluated which individual factors of renal nephrometry score (RNS) influenced the operative approach bi-annually from 2008 to 2014. Materials and Methods: We performed a retrospective review of renal cell carcinoma treated by...

  • Gender differences in clinicopathological features and survival in surgically treated patients with renal cell carcinoma: an analysis of the multicenter CORONA database. May, Matthias; Aziz, Atiqullah; Zigeuner, Richard; Chromecki, Thomas; Cindolo, Luca; Schips, Luigi; Cobelli, Ottavio; Rocco, Bernardo; Nunzio, Cosimo; Tubaro, Andrea; Coman, Ioman; Truss, Michael; Dalpiaz, Orietta; Hoschke, Bernd; Gilfrich, Christian; Feciche, Bogdan; Stoltze, Anette; Fenske, Fabian; Fritsche, Hans-Martin; Figenshau, Robert // World Journal of Urology;Oct2013, Vol. 31 Issue 5, p1073 

    Purpose: To investigate gender differences in clinicopathological features and to analyze the prognostic impact of gender in renal cell carcinoma (RCC) patients undergoing surgery. Methods: A total of 6,234 patients (eleven centers; Europe and USA) treated by radical or partial nephrectomy were...

  • Angiotensin system inhibitors extended PFS, OS in renal cell carcinoma.  // Hem/Onc Today;3/10/2014, Vol. 15 Issue 5, p24 

    The article discusses research being done on the use of angiotensin system inhibitors in patients with renal cell carcinoma, which references a study by Rana McKay et al. presented at the 2014 Genitourinary Cancers Symposium in San Francisco, California.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics